Loading provider…
Loading provider…
Medical Oncology Physician in Ypsilanti, MI
NPI: 1174576219Primary Practice Location
IHA Hematology Oncology Consultants
5303 Elliott Dr, Ypsilanti, MI
Primary Employer
IHA Hematology Oncology Consultants
ihacares.com
HQ Phone
Get MD Elie's Phone Numberphone_androidMobile
Get MD Elie's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardSD State Medical License
NY State Medical License
MI State Medical License
MI State Medical License
2014 - 2027
NY State Medical License
2005 - 2027
SD State Medical License
2027
MA State Medical License
2022 - 2026

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
University of Rochester Medical Center
urmc.rochester.edu
Fellowship • Hematology and Medical Oncology
2003 - 2006
Johns Hopkins University Advanced Academic Programs
Masters • Individualized Genomics and Health
2019 - 2022
Harvard Medical School
hms.harvard.edu
Post-Graduate Program • Cancer Biology & Therapeutics: High Impact Cancer Research
2018 - 2019
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 220 | 378 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 110 | 179 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 66 | 80 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 39 | 39 |
| 5 | M0010Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 34 | 159 |
Olaparib in Patients With Metastatic Prostate Cancer With/Mutation: Results From the TAPUR Study.
Authors: Mehmet Bilen, Nitin Rohatgi, Earle Burgess, Michael Zakem
Journal: JCO Precis Oncol
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Nivolumab, DRUG: Pembrolizumab, DRUG: Atezolizumab, DRUG: Avelumab, DRUG: Durvalumab
Lead Sponsor: University of Rochester NCORP Research Base
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Quality-of-Life Assessment, OTHER: Survey Administration, BEHAVIORAL: Telephone-Based Intervention, OTHER: Educational Intervention, OTHER: Behavioral, Psychological or Informational Intervention, PROCEDURE: Medical Examination Assessment
Lead Sponsor: Alliance Foundation Trials, LLC.
Collaborators: Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Intervention / Treatment: DRUG: Lenalidomide, DRUG: Dexamethasone, DRUG: Ixazomib, DRUG: Daratumumab Injection